FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington,	D.C.	20549		

OIVID AFFRC	/VAL				
OMB Number:	3235-0287				
Estimated average burd	en				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hudson Frederick M.</u>					2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]								5. Relationship of Reporting (Check all applicable) X Director			g Per	g Person(s) to Issuer 10% Owner			
	`	HARMACEUTI	(Middle) CALS, IN	C.		3. Date of Earliest Transaction (Month/Day/Year) 02/22/2022									Officer below)	(give title		Other (s	specify	
(Street) ROCKVILLE MD 20850 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing Line) X Form filed by One Report Form filed by More than Person									orting Perso	n					
		Tab	le I - Non	-Deriv	ative	Se	curities	s Ac	quire	d, D	isp	osed o	of, or Be	enefic	cially	/ Owned				
1. Title of Security (Instr. 3) 2. Trans Date					2A. Deemed Execution Date, if any (Month/Day/Yea			e, Transaction Dispos Code (Instr. 5)		Dispose	ities Acqui d Of (D) (Ir		or 5. Amount of Securities Beneficially Owned Follo		s Forn ally (D) o ollowing (I) (Ir		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
								Cod	de V	/	Amount (A)		or Pr	rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock														22	22,263		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,		ransaction of E ode (Instr. Derivative (M		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)				3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercis	able	Ex	piration te	Title	Amo or Num of Shar	ber					
Director Stock Option (Right to Buy)	\$32.2	02/22/2022			A		6,847		02/22/2	2023	02/	/22/2032	Common Stock	6,8	47	\$0	6,847		D	
Restricted Stock	(1)	02/22/2022			A		3.882		(2)			(2)	Common	3.8	82	\$0	3,882		D	

Explanation of Responses:

- 1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- 2. These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Timothy C. Dec, as attorney-in-fact

02/24/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney

Know all by these presents, that the undersigned hereby constitutes and appoints JACK KHATTAR and TIMOTHY DEC, and each of them individually, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of Supernus Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any securities exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and condition as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in- fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS THEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of October, 2021.

/s/ Frederick M. Hudson	
Frederick M. Hudson	